Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir

Antiviral Therapy

Volumn 19, Issue 3, 2014, Pages 259-267

  De Niet, Annikki ^a   Jansen, Louis ^a   Zaaijer, HansL ^a   Klause, Ursula ^b   Takkenberg, Bart ^a   Janssen, Harry L A ^c   Chu, Tom ^d   Petric, Rosemary ^d   Reesink, Hendrik W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA; ADENINE; ALPHA INTERFERON; ANTIGEN ANTIBODY COMPLEX; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ADULT; ANALYTICAL EQUIPMENT; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG MONITORING; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PROTEIN MICROARRAY; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ADULT; ANTIGEN-ANTIBODY COMPLEX; ANTIVIRAL AGENTS; AREA UNDER CURVE; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84902679110     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2707     Document Type: Article

References (28)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.
2. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129.
3. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137:2002-2009.
4. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
5. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011; 7:429-436.
6. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52:1251-1257.
7. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
8. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56:1006-1011.
9. Gane E, Jia J, Han K, et al. Neptune study: on-treatment HBsAg level analysis confirms prediction of response observed in Phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. J Hepatol 2011; 54 Supp 1:S31.
10. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-1188.
11. Takkenberg RB, Zaaijer HL, Weegink CJ, et al. Baseline HBsAg level predict HBsAg loss in HBeAg negative chronic hepatitis B patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysis. J Hepatol 2009; 50 Supp 1:S9-S10.
12. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2. J Hepatol 2011; 55:1121-1131.
13. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:68-76.
14. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99:1472-1477.
15. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191:1269-1280.
16. Koo YX, Tan DS, Tan IB, Tao M, Lim ST. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2009; 150:655-656.
17. Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116:4769-4776.
18. Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90:1219-1223.
19. Zaaijer HL, Lelie PN, Vandenbroucke-Grauls CM, Koot M. Concurrence of hepatitis B surface antibodies and surface antigen: implications for postvaccination control of health care workers. J Viral Hepat 2002; 9:146-148.
20. Shiels MT, Taswell HF, Czaja AJ, Nelson C, Swenke P. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B. Gastroenterology 1987; 93:675-680.
21. Pondé RA. The underlying mechanisms for the 'simultaneous HBsAg and anti-HBs serological profile'. Eur J Clin Microbiol Infect Dis 2011; 30:1325-1340.
22. Madalinski K, Burczynska B, Heermann KH, Uy A, Gerlich WH. Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 1991; 84:493-500.
23. Takkenberg RB, Jansen L, de Niet A, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir. Antivir Ther 2013; 18:895-904.
24. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
25. Gerlich WH. Diagnostic problems caused by HBsAg mutants-a consensus report of an expert meeting. Intervirology 2004; 47:310-313.
26. Rizetto M. Hepatitis delta virus infection: clinical and epidemiological aspects. In AJ Zuckerman (Editor). Viral hepatitis and liver disease. New York: Alan R Liss, Inc. 1988; pp. 389-394.
27. + T cell memory. J Immunol 2009; 182:1868-1876.
28. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428-434.